These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18064861)

  • 1. [The influence of the pharmaceutical industry in patient organisations].
    Vermeulen M; Bouma J
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2432-4. PubMed ID: 18064861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-operation between patient organisations and the drug industry in Finland.
    Hemminki E; Toiviainen HK; Vuorenkoski L
    Soc Sci Med; 2010 Apr; 70(8):1171-5. PubMed ID: 20163903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.
    Ball DE; Tisocki K; Herxheimer A
    BMC Public Health; 2006 Aug; 6():201. PubMed ID: 16887025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
    Rickard E; Ozieranski P; Mulinari S
    Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In diabetes fight, raising cash and keeping trust.
    Santora M
    N Y Times Web; 2006 Nov; ():A1, B4. PubMed ID: 17167875
    [No Abstract]   [Full Text] [Related]  

  • 6. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
    Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K
    Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The influence of the pharmaceutical industry on treatment guidelines].
    Kramers C; Wuis E; Schouwenberg B
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):114; author reply 114. PubMed ID: 18265803
    [No Abstract]   [Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of the pharmaceutical industry on treatment guidelines].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2429-31. PubMed ID: 18064860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines.
    Cosgrove L; Bursztajn HJ; Krimsky S; Anaya M; Walker J
    Psychother Psychosom; 2009; 78(4):228-32. PubMed ID: 19401623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption?
    Spelsberg A; Martiny A; Schoenhoefer PS;
    J Epidemiol Community Health; 2009 Aug; 63(8):603-5. PubMed ID: 19596840
    [No Abstract]   [Full Text] [Related]  

  • 12. Exposing drug industry funding of UK patient organisations.
    Ozieranski P; Rickard E; Mulinari S
    BMJ; 2019 May; 365():l1806. PubMed ID: 31122928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACOG Committee Opinion No. 401: Relationships with industry.
    American College of Obstetricians and Gynecologists Committee on Ethics
    Obstet Gynecol; 2008 Mar; 111(3):799-804. PubMed ID: 18310391
    [No Abstract]   [Full Text] [Related]  

  • 14. General Council to consider amendments to CMA policy on MDs' relationships with drug industry.
    Williams JR
    CMAJ; 1993 Aug; 149(3):335-7. PubMed ID: 11659649
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widening the debate about conflict of interest: addressing relationships between journalists and the pharmaceutical industry.
    Lipworth W; Kerridge I; Sweet M; Jordens C; Bonfiglioli C; Forsyth R
    J Med Ethics; 2012 Aug; 38(8):492-5. PubMed ID: 22431558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sponsoring of medical conferences, workshops and symposia by pharmaceutical companies. Physicians must be wary of this!].
    Warntjen M
    Anaesthesist; 2009 Dec; 58(12):1256-60. PubMed ID: 20012247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial relationships between research and pharmaceutical/biotech companies: disclosure is imperative.
    Caughey AB; Urato AC
    Am J Obstet Gynecol; 2007 Jan; 196(1):e13; author reply e13-4; discussion e14. PubMed ID: 16959207
    [No Abstract]   [Full Text] [Related]  

  • 20. How to manage conflicts of interest with industry?
    Schowalter JE
    Int Rev Psychiatry; 2008 Apr; 20(2):127-33. PubMed ID: 18386202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.